Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Accounts Payables: 2017-2025

Historic Accounts Payables for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $4.4 million.

  • Cidara Therapeutics' Accounts Payables rose 46.65% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 46.65%. This contributed to the annual value of $3.6 million for FY2024, which is 4.35% down from last year.
  • As of Q3 2025, Cidara Therapeutics' Accounts Payables stood at $4.4 million, which was up 97.23% from $2.2 million recorded in Q2 2025.
  • Cidara Therapeutics' 5-year Accounts Payables high stood at $5.1 million for Q1 2024, and its period low was $1.3 million during Q4 2021.
  • Its 3-year average for Accounts Payables is $3.5 million, with a median of $3.7 million in 2023.
  • Its Accounts Payables has fluctuated over the past 5 years, first slumped by 71.52% in 2021, then surged by 160.68% in 2023.
  • Cidara Therapeutics' Accounts Payables (Quarterly) stood at $1.3 million in 2021, then climbed by 11.22% to $1.4 million in 2022, then skyrocketed by 160.68% to $3.8 million in 2023, then declined by 4.35% to $3.6 million in 2024, then spiked by 46.65% to $4.4 million in 2025.
  • Its Accounts Payables was $4.4 million in Q3 2025, compared to $2.2 million in Q2 2025 and $4.9 million in Q1 2025.